Origins and molecular pathology of ovarian cancer

被引:292
作者
Bell, DA
机构
[1] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
ovarian cancer; ovarian borderline tumors; histogenesis; molecular pathology;
D O I
10.1038/modpathol.3800306
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Epithelial ovarian cancer comprises the majority of malignant ovarian tumors in adult women. These neoplasms are classified into distinct morphologic categories based on the appearance of the epithelium into tumors of serous, mucinous, endometrioid, clear cell, transitional, squamous, mixed and undifferentiated type. Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands with TP53 mutations and dysfunction of BRCA1 and/or BRCA2; low-grade serous carcinomas probably arise in a stepwise fashion in an adenoma-borderline tumor-carcinoma sequence from typical to micropapillary borderline tumors to low-grade invasive serous carcinoma via activation of the RAS-RAF signaling pathway secondary to mutations in KRAS and BRAP, mucinous carcinomas arise via an adenoma-borderline tumor-carcinoma sequence with mutations in KRAS; low-grade endometrioid carcinomas arise from endometriosis via mutations in CTNNB1 (the gene encoding beta-catenin) and PTEN. Although the morphologic data strongly support an origin of clear cell carcinoma from endometriosis, there is limited data on the genetic alterations in these uncommon tumors. Thus it is likely that most low-grade, relatively indolent ovarian carcinomas of serous, mucinous and endometrioid type arise from pre-existing cystadenomas or endometriosis whereas most high-grade serous carcinomas arise without an easily identifiable precursor lesion.
引用
收藏
页码:S19 / S32
页数:14
相关论文
共 160 条
  • [1] Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or-2 mutations - Implications for gross examination, cytology, and clinical follow-up
    Agoff, SN
    Mendelin, JE
    Grieco, VS
    Garcia, RL
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (02) : 171 - 178
  • [2] Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO
  • [3] 2-3
  • [4] Auersperg N, 1998, SEMIN ONCOL, V25, P281
  • [5] AURE JC, 1971, ACTA OBSTET GYN SCAN, V50, P63
  • [6] Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust
    Balkwill, F
    Bast, RC
    Berek, J
    Chenevix-Trench, G
    Gore, M
    Hamilton, T
    Jacobs, I
    Mills, G
    Souhami, R
    Urban, N
    Ursulic, S
    Smyth, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (13) : 1818 - 1827
  • [7] OVARIAN ENDOMETRIOTIC CYSTS - AN ANALYSIS OF CYTOLOGIC ATYPIA AND DNA-PLOIDY PATTERNS
    BALLOUK, F
    ROSS, JS
    WOLF, BC
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (04) : 415 - 419
  • [8] Barakat RR, 2000, CANCER, V89, P383, DOI 10.1002/1097-0142(20000715)89:2<383::AID-CNCR25>3.0.CO
  • [9] 2-T
  • [10] BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO